Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | Upcoming MRI biomarkers in multiple sclerosis

Jaume Sastre-Garriga, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the future of MRI in the diagnosis of multiple sclerosis (MS) and describes novel imaging biomarkers. The central vein sign, optic nerve lesions, and paramagnetic rim lesions are emerging imaging biomarkers in MS that might be included in the diagnostic criteria. Prof. Sastre-Garriga highlights the importance of exploring the use of MRI measurements as prognostic biomarkers in MS. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


J Sastre-Garriga has received grants and personal fees from Genzyme, personal fees from Almirall, Biogen, Celgene, Merck, Bayer, Biopass, Bial, Novartis, Roche and Teva, and he is European co-Editor of Multiple Sclerosis Journal and Scientific Director of Revista de Neurologia.